Our mission is to develop
and commercialize novel
and best-in-class therapeutics
to address unmet medical needs
in the emerging otology market

AuriPro™

A sustained-exposure formulation of the antibiotic ciprofloxacin that has completed Phase 3 trials for the treatment of middle ear effusion in pediatric patients requiring tympanostomy tube placement (TTP) surgery....
LEARN MORE »

OTO-104

A sustained-exposure formulation
of the steroid dexamethasone that
is in a Phase 2b clinical trial for
patients with Ménière’s disease....
LEARN MORE »

OTO-311

A sustained-exposure formulation
of the NMDA receptor antagonist
gacyclidine in development for
the treatment of tinnitus....
LEARN MORE »